Stockscreener 앱 받기
21.79
3.91%
0.82
전일 마감가:
$20.97
열려 있는:
$21.64
하루 거래량:
130.98K
Relative Volume:
1.18
시가총액:
$1.26B
수익:
-
순이익/손실:
$-75.28M
주가수익비율:
-10.92
EPS:
-1.9957
순현금흐름:
$-57.45M
1주 성능:
+9.11%
1개월 성능:
+5.83%
6개월 성능:
+16.90%
1년 성능:
+16.52%
1일 변동 폭
$21.33
$21.93
1주일 범위
$19.70
$22.14
52주 변동 폭
$14.00
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
OCS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
21.82 | 1.21B | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.74 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
815.13 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
414.79 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.24 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
171.29 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-19 | 개시 | JP Morgan | Overweight |
| 2025-08-27 | 개시 | Needham | Buy |
| 2023-12-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-10-05 | 개시 | Stifel | Buy |
| 2023-06-14 | 개시 | BofA Securities | Buy |
| 2023-06-12 | 개시 | H.C. Wainwright | Buy |
| 2023-06-08 | 개시 | Robert W. Baird | Outperform |
| 2023-05-10 | 개시 | Pareto | Buy |
| 2023-04-28 | 개시 | Wedbush | Outperform |
모두보기
Oculis Holding Ag 주식(OCS)의 최신 뉴스
Oculis Holding Ag Announces the Transformative Potential of Its Late-Stage Pipeline - MarketScreener
Is Oculis Holding AG Equity Warrant stock positioned well for digital economyFibonacci Retracement Levels & Unlock Smart Investment Tactics That Work - ulpravda.ru
Oculis Holding AG Advances PIONEER Program with Breakthrough Therapy Designation for Privosegtor and Prepares for Upcoming J.P. Morgan Healthcare Conference Presentation - Quiver Quantitative
Experimental eye drugs target vision loss in diabetes and optic nerve disease - Stock Titan
FDA grants Breakthrough Therapy Designation to Oculis' privosegtor for optic neuritis - Eyes On Eyecare
Should I hold or sell Oculis Holding AG Equity Warrant stock in 20252026 world cup usa national team qualification goalkeepers transition play odds analysis insights - ulpravda.ru
How Oculis Holding AG Equity Warrant stock benefits from tech adoption2026 world cup usa national team qualification star players transition play knockout prediction guide - ulpravda.ru
What drives Oculis Holding AG stock priceDouble Top/Bottom Patterns & Free Stay Ahead With Picks - earlytimes.in
Oculis (NASDAQ:OCS) Shares Gap UpShould You Buy? - MarketBeat
Oculis gains on FDA breakthrough therapy status (OCS:NASDAQ) - Seeking Alpha
Oculis stock surges after FDA grants breakthrough therapy designation By Investing.com - Investing.com Nigeria
Oculis stock surges after FDA grants breakthrough therapy designation - Investing.com
Aug Rallies: Can Oculis Holding AG CR5 stock surprise with quarterly resultsEarnings Beat & Reliable Breakout Forecasts - moha.gov.vn
Oculis Holding AG Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis - MarketScreener
Oculis Holding Says FDA Granted Breakthrough Therapy Designation for Privosegtor - marketscreener.com
Oculis Holding AG's Privosegtor Receives Breakthrough Therapy Designation for Optic Neuritis Treatment - Quiver Quantitative
Oculis tilkynnir um að Matvæla- og lyfjastofnun - GlobeNewswire
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewswire
How Oculis Holding Ag (OCS) Affects Rotational Strategy Timing - Stock Traders Daily
Wall Street analysts predict a 106.04% upside in Oculis Holding AG (OCS): Here's what you should know - MSN
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Short Interest in Oculis Holding AG (NASDAQ:OCS) Increases By 105.6% - MarketBeat
Discipline and Rules-Based Execution in OCS Response - Stock Traders Daily
Assessing Oculis Holding (NasdaqGM:OCS) Valuation After FDA Backing for OCS‑05 and PIONEER Program Progress - simplywall.st
Oculis (NASDAQ:OCS) Shares Down 4.3%Time to Sell? - MarketBeat
Net current asset value per share of Oculis Holding AG – FWB:CR5 - TradingView — Track All Markets
Cash per share of Oculis Holding AG Warrants 2023-06.03.28 on OCULIS HOLDING – NASDAQ:OCSAW - TradingView — Track All Markets
Why analysts upgrade Oculis Holding AG Equity Warrant stock2025 Buyback Activity & Safe Entry Zone Tips - Улправда
Advancing Privosegtor Toward PIONEER Registrational Trials Could Be A Game Changer For Oculis (OCS) - simplywall.st
Is Oculis Holding AG (CR5) stock cheap vs fundamentalsQuarterly Market Summary & Daily Technical Forecast Reports - Улправда
Why Oculis Holding AG Equity Warrant stock attracts global investorsMarket Sentiment Summary & Long-Term Growth Stock Strategies - Улправда
Can Oculis Holding AG stock deliver surprise earnings beatMarket Activity Recap & AI Based Buy/Sell Signal Reports - Улправда
How Oculis Holding AG Equity Warrant stock reacts to inflationary pressuresMarket Rally & Low Risk Growth Stock Ideas - Улправда
Take Profit: How Oculis Holding AG Equity Warrant stock benefits from tech adoptionWeekly Market Outlook & Daily Technical Forecast Reports - Улправда
Oculis (NASDAQ:OCS) Given New $40.00 Price Target at Stifel Nicolaus - Defense World
Oculis (NASDAQ:OCS) Now Covered by JPMorgan Chase & Co. - Defense World
Why Oculis Holding AG stock could benefit from AI revolutionJuly 2025 Technicals & Consistent Profit Trade Alerts - Улправда
Oculis (NASDAQ:OCS) Shares Gap Up on Analyst Upgrade - Defense World
What sentiment indicators say about Oculis Holding AG stock2025 Volume Leaders & Momentum Based Trading Ideas - Улправда
Oculis stock price target raised to $40 by Stifel on neuro-ophthalmology progress - Investing.com South Africa
Stifel Maintains Oculis Holding (OCS) Buy Recommendation - Nasdaq
Can Oculis Holding AG stock sustain revenue growthDividend Hike & Growth Focused Entry Point Reports - Улправда
Will Oculis Holding AG stock rally after Fed decisionsWeekly Trend Recap & Consistent Income Trade Ideas - Улправда
Oculis (NASDAQ:OCS) Shares Gap Up After Analyst Upgrade - MarketBeat
Oculis (NASDAQ:OCS) Price Target Raised to $40.00 at Stifel Nicolaus - MarketBeat
JP Morgan Initiates Coverage on OCS with Overweight Rating | OCS Stock News - GuruFocus
Oculis (NASDAQ:OCS) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat
Recap Report: Is Oculis Holding AG Equity Warrant stock undervalued vs historical averages2025 Price Targets & Entry and Exit Point Strategies - Улправда
JPMorgan Initiates Coverage on Oculis Holding AG With Overweight Rating, $38 Price Target - marketscreener.com
Will Oculis Holding AG Equity Warrant stock split attract more investors2025 Earnings Surprises & Risk Adjusted Buy and Sell Alerts - Bölüm Sonu Canavarı
Why Oculis Holding AG Equity Warrant stock could rally in 2025Gold Moves & Free Community Supported Trade Ideas - DonanımHaber
Oculis Holding Ag (OCS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.23%
자본화:
|
볼륨(24시간):